Background: Cardiovascular intensive care unit (CICU) is an area with high mortality rates globally. The prediction of inpatients mortality risk at CICU needs a simplified scoring systems. Hence, this study aims to analyze the predictors for in-hospital mortality of patients whom hospitalized at CICU of Sardjito General Hospital Yogyakarta and to create a mortality risk score based on the results of this analysis. Methods: Data were obtained from SCIENCE (Sardjito Cardiovascular Intensive Care) registry. Outcomes of 595 consecutive patients (mean age 59.92 +/- 13.0 years) from January to November 2017 were recorded retrospectively. Demography, risk factor, comorbidities, laboratory result and other examinations were analyzed by multivariate logistic regression to create two models of scoring system (probability and cut-off model) to predict in-hospital mortality of any cause. Results: A total of 595 subjects were included in this research; death was found in 55 patients (9.2%). Multiple logistic regression analysis showed some variables that became independent predictor of mortality, i.e. age >= 60 years, pneumonia, the use of ventilator machine, and increased of serum glutamate-pyruvate transaminase level, an increased of creatinine level and an ejection fraction < 40%. Receiver operating characteristic (ROC) curve analysis showed a cut-off model scoring system with score 3 to 9 predicting mortality compared to score 0 - 2. This model yielded sensitivity of 80% and specificity 74%. While the probability scoring system (score 0 to 9) showed that the higher the score, the higher the mortality probability (e.g. the mortality of patient with score 2 is 5.27%; while the mortality of patient with score 8 is 87.5%). Conclusions: Scoring system derived from this study can be used to predict the in-hospital mortality of patients whom hospitalized in our CICU and show a favorable sensitivity and specificity result.
Background and objectives: The application of prognostic scoring systems to identify risk of death within 24 h of CICU admission has significant consequences for clinical decision-making. Previous score of parameters collected after 24 h was considered too late to predict mortality. As a result, we attempted to develop a CICU admission risk score to predict hospital mortality using indicators collected within 24 h.Methods: Data were obtained from SCIENCE registry from January 1, 2021 to December 21, 2021. Out-comes of 657 patients (mean age 58.91 +/- 12.8 years) were recorded retrospectively. Demography, risk factors, comorbidities, vital signs, laboratory and echocardiography data at 24-h of patient admitted to CICU were analysed by multivariate logistic regression to create two models of scoring system (proba-bility and cut-off model) to predict in-hospital mortality of any cause.Results: From a total of 657 patients, the hospital mortality was 15%. The significant predictors of mor-tality were male, acute heart failure, hemodynamic instability, pneumonia, baseline creatinine >= 1.5 mg/ dL, TAPSE = 3 is considered to be a high risk of in-hospital mortality (sensitivity 75% and specificity 65%). Conclusion: The initial 24-h SCIENCE admission risk rating system can be used to predict in-hospital mortality in patients admitted to the CICU with a high degree of sensitivity and specificity,(c) 2022 Cardiological Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd.This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Aims: This study aimed to conduct a phase 2 proof-of-concept and safety study to evaluate the effect of ENIBARCIMAB (EN), a non-neutralizing humanized monoclonal antibody targeting the N-terminus of adrenomedullin (ADM), administered immediately after stabilization with standard of care (SoC) treatment, in patients hospitalized for acute heart failure (AHF). Methods and results: This prospective, open-label, controlled, interventional, multicenter, dose-escalation study was conducted at two cardiology sites in Indonesia. Patients were divided into two interventional groups sequentially receiving 0.5 mg/kg (SoC + EN 0.5 mg/kg, n = 10; first cohort) and 2 mg/kg (SoC + EN 2 mg/kg, n = 10; second cohort) of EN via 1-h intravenous (IV) infusion within 48 h after admission for AHF. The control group (n = 10) was treated with SoC therapy for AHF therapy. All patients were monitored continuously within 24 h post-infusion and subsequent daily until discharge. Treatment-related serious adverse events (SAEs) were recorded during hospitalization and up to 90 days after discharge. Both EN dosages were well-tolerated, and no significant safety issues were identified during hospitalization and up to 90 days of follow up. SAEs occurred in 10% of patients in each EN group but were deemed not related to treatment. No significant differences in the occurrence of SAEs were found between the groups. Five deaths occurred: three (30%) in the control group as compared with two deaths (20%) in the SoC + EN 2 mg/kg group. EN led to a significant increase in plasma bio-ADM levels within 24 h post-infusion, with the SoC + 2 mg/kg group showing the highest increase. Within 1 h from IV EN infusion, SoC + EN 2 mg/kg compared with 0.5 mg/kg, resulted in a significant percentage reduction in systolic, diastolic blood pressure, and mean arterial pressure. However, it did not result in severe hypotension and the need for drug discontinuation. Conclusions: In this pilot safety study of patients hospitalized for AHF, IV infusion of EN 0.5 and 2 mg/kg increased circulating plasma bio-ADM levels and was well-tolerated without treatment-related SAEs occurring during hospitalization and up to 90 days after discharge.
2 August 2016 in Journal of the Medical Sciences (Berkala Ilmu Kedokteran)
Rotational atherectomy (RA) is a proven technique to modify a heavily calcified coronary lesion if balloon angioplasty failed. RA is frequently avoided in ST-elevation myocardial infarction (STEMI) as it may increase the risk of slow or no-reflow. It is also considered to be relatively contraindicated in lesions with a visible thrombus, by its manufacturer. Regardless, RA may be a life-saving procedure in cases where no other percutaneous coronary intervention (PCI) technique is available to modify the lesion adequately. This case reports successful use of RA to facilitate dilation and stent delivery of a previously non-dilatable lesion in a patient with sub-acute anterior STEMI complicated by cardiogenic shock.
Background: The incidence of mortality in patients with cardiogenic shock due to ST elevation myocardial infarction (STEMI) remains high even with prompt reperfusion therapy. Ventricular systolic dysfunction is the primary condition causing cardiogenic shock in STEMI. Studies have been widely conducted on the left ventricle (LV) and right ventricle (RV) systolic dysfunction related to mortality events. However, the parameters of biventricular systolic dysfunction predicting mortality as a stronger predictor of mortality are still unclear. Accordingly, we evaluated the predictor mortality value of biventricular systolic dysfunction in STEMI patients with cardiogenic shocks. Based on The Society for Cardiovascular Angiography and Intervention classification, we analyzed data from November 2021 to September 2023 at Dr. Sardjito General Hospital in Yogyakarta, Indonesia, using the Sardjito Cardiovascular Intensive Care (SCIENCE) registry with a retrospective cohort design. Multivariate logistic regression analysis was used to assess predictors of in-hospital mortality. Results: There were 1,059 subjects with a mean ± SD age of 59 ± 11 years, dominated by men (80.5%) who met the inclusion and exclusion criteria. Based on multivariate analysis, biventricular dysfunction (BVD) is a factor that significantly increases the risk of in-hospital mortality (Odds ratio [OR], 1.771: 95% confidence interval [CI] 1.113–2.819; p = 0.016). Other significant factors affecting mortality were renal failure (OR, 5.122; 95% CI 3.233–8.116; p < 0.001), percutaneous coronary intervention (PCI) (OR, 0.493; 95% CI 0.248–0.981; p = 0.044), and inotropic/vasopressor (OR, 6.876; 95% CI 4.583–10.315; p < 0.001). Conclusions: Biventricular dysfunction significantly increases the risk of in-hospital mortality in STEMI patients with cardiogenic shock. Renal failure, PCI, and the requirement for inotropic or vasopressor drugs are also factors that influence in-hospital mortality.